P

PERROTTI G.

Last name: PERROTTI G.

2019 (v1)

Publication

Metadata-only

In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity

D'Antona L. Dattilo V. Catalogna G.

Ovarian cancer is the second most common gynecological malignancy worldwide. Paclitaxel is particularly important in the therapy of ovarian carcinomas, but the treatment efficacy is counteracted by the development of resistance to chemotherapy. The identification of target molecules that can prevent or control the development of chemoresistance...

Uploaded on: April 14, 2023